These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36921770)

  • 1. Interest in using buprenorphine-naloxone among a prospective cohort of street-involved young people in Vancouver, Canada.
    Pilarinos A; Bingham B; Kwa Y; Joe R; Grant C; Fast D; Buxton JA; DeBeck K
    J Subst Use Addict Treat; 2023 May; 148():209005. PubMed ID: 36921770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
    Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
    Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada.
    Pilarinos A; Kwa Y; Joe R; Dong H; Grant C; Fast D; Buxton JA; DeBeck K
    Can J Psychiatry; 2023 Feb; 68(2):89-100. PubMed ID: 36377240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of opioid agonist treatment and subsequent substance use and other patterns among adolescents and young adults in Vancouver, Canada.
    Pilarinos A; Fast D; Nosova E; Kwa Y; Joe R; Buxton JA; DeBeck K
    Drug Alcohol Depend; 2022 Jun; 235():109441. PubMed ID: 35427979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
    Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
    Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.
    Young S; Hayashi K; Grant C; Milloy MJ; DeBeck K; Wood E; Fairbairn N
    Drug Alcohol Depend; 2021 Nov; 228():109006. PubMed ID: 34509737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing - a case series.
    Brar R; Fairbairn N; Sutherland C; Nolan S
    Drug Alcohol Rev; 2020 Jul; 39(5):588-594. PubMed ID: 32657496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
    Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
    Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
    Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
    Pilarinos A; Kwa Y; Joe R; Thulien M; Buxton JA; DeBeck K; Fast D
    Int J Drug Policy; 2022 Sep; 107():103773. PubMed ID: 35780565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
    Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
    Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.
    Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P
    J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.
    Carroll JJ; Rich JD; Green TC
    J Addict Med; 2018; 12(6):459-465. PubMed ID: 30095563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 20. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.